Corcept Therapeutics Inc
CORT80.280USD
+2.570+3.31%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
8.44BMarket Cap
79.53P/E TTM
More Details of Corcept Therapeutics Inc Company
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Corcept Therapeutics Inc Info
Ticker SymbolCORT
Company nameCorcept Therapeutics Inc
IPO dateApr 15, 2004
CEODr. Joseph K. Belanoff, M.D.
Number of employees500
Security typeOrdinary Share
Fiscal year-endApr 15
Address101 Redwood Shores Parkway
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16506888803
Websitehttps://www.corcept.com/
Ticker SymbolCORT
IPO dateApr 15, 2004
CEODr. Joseph K. Belanoff, M.D.
Company Executives of Corcept Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-0.02%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.60K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
36.03K
+0.69%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.32K
+1.82%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.28K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.29K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-0.02%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.60K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
36.03K
+0.69%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
Other
62.41%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
Other
62.41%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.89%
Investment Advisor/Hedge Fund
22.83%
Individual Investor
11.63%
Hedge Fund
7.39%
Pension Fund
1.39%
Sovereign Wealth Fund
0.96%
Research Firm
0.74%
Bank and Trust
0.43%
Family Office
0.06%
Other
12.68%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
791
81.34M
77.33%
-10.47M
2025Q2
740
96.93M
91.97%
-8.00M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
11.31M
10.74%
-1.71M
-13.12%
Jun 30, 2025
The Vanguard Group, Inc.
9.66M
9.17%
-301.38K
-3.03%
Jun 30, 2025
Ingalls & Snyder LLC (Asset Management)
7.72M
7.33%
-19.66K
-0.25%
Jun 30, 2025
Renaissance Technologies LLC
6.27M
5.95%
+123.37K
+2.01%
Jun 30, 2025
Baker (George Leonard Jr.)
5.31M
5.04%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.87M
3.67%
-101.29K
-2.55%
Jun 30, 2025
Belanoff (Joseph K)
2.98M
2.83%
-615.00
-0.02%
Jul 17, 2025
State Street Investment Management (US)
2.97M
2.82%
-434.35K
-12.77%
Jun 30, 2025
Wilson (James N)
2.35M
2.23%
+129.14K
+5.82%
Apr 17, 2025
Fidelity Management & Research Company LLC
1.36M
1.29%
-121.95K
-8.25%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
4.95%
Formidable ETF
4.17%
First Trust NYSE Arca Biotechnology Index Fund
3.59%
Invesco Pharmaceuticals ETF
3.19%
iShares U.S. Pharmaceuticals ETF
2.88%
SPDR S&P Pharmaceuticals ETF
2.79%
Alger Russell Innovation ETF
2.28%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.09%
Fidelity Stocks for Inflation ETF
1.77%
Invesco S&P SmallCap 600 Pure Growth ETF
1.76%
View more
Invesco S&P SmallCap Health Care ETF
Proportion4.95%
Formidable ETF
Proportion4.17%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.59%
Invesco Pharmaceuticals ETF
Proportion3.19%
iShares U.S. Pharmaceuticals ETF
Proportion2.88%
SPDR S&P Pharmaceuticals ETF
Proportion2.79%
Alger Russell Innovation ETF
Proportion2.28%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.09%
Fidelity Stocks for Inflation ETF
Proportion1.77%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.76%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Corcept Therapeutics Inc?
The top five shareholders of Corcept Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 11.31M shares, accounting for 10.74% of the total shares.
The Vanguard Group, Inc. holds 9.66M shares, accounting for 9.17% of the total shares.
Ingalls & Snyder LLC (Asset Management) holds 7.72M shares, accounting for 7.33% of the total shares.
Renaissance Technologies LLC holds 6.27M shares, accounting for 5.95% of the total shares.
Baker (George Leonard Jr.) holds 5.31M shares, accounting for 5.04% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.31M shares, accounting for 10.74% of the total shares.
The Vanguard Group, Inc. holds 9.66M shares, accounting for 9.17% of the total shares.
Ingalls & Snyder LLC (Asset Management) holds 7.72M shares, accounting for 7.33% of the total shares.
Renaissance Technologies LLC holds 6.27M shares, accounting for 5.95% of the total shares.
Baker (George Leonard Jr.) holds 5.31M shares, accounting for 5.04% of the total shares.
What are the top three shareholder types of Corcept Therapeutics Inc?
The top three shareholder types of Corcept Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
How many institutions hold shares of Corcept Therapeutics Inc (CORT)?
As of 2025Q3, 791 institutions hold shares of Corcept Therapeutics Inc, with a combined market value of approximately 81.34M, accounting for 77.33% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.64%.
What is the biggest source of revenue for Corcept Therapeutics Inc?
In --, the -- business generated the highest revenue for Corcept Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
